In an apiary somewhere in the American South last spring, a commercial beekeeper tipped a paper bag of beige powder into a liter of sugar syrup and walked it out to a row of hives. The powder was dead bacteria. Within a week, in a sequence of events invisible to the beekeeper, those dead bacteria would be carried into the queen of the nearest colony, bound to a yolk protein, ferried into her eggs, and waiting there when her daughters hatched.
The hive had no antibodies. Honeybees, like every insect on Earth, lack the B-cell machinery that defines vertebrate immunity, the lineage of plasma cells and rearranged immunoglobulin genes that, in mammals, learns to recognize yesterday's invader. And yet by every meaningful measure, the colony was now protected. The U.S. Department of Agriculture had, in January 2023, granted a conditional license to a vaccine for American Foulbrood, a bacterial infection that has historically meant one thing for an infected hive: a lit match [1][2].
A First Vaccine for an Animal Without Antibodies
American Foulbrood is caused by Paenibacillus larvae, a gram-positive, spore-forming bacterium whose resting spores can survive inside hive equipment for decades [3]. The disease is so destructive that, in some jurisdictions, the only legal response to an outbreak is to burn the colony, frames, honey, and all [11]. Honeybee larvae are most vulnerable in the first 24 to 72 hours after they hatch, and once symptoms appear in a hive it is usually too late to do anything but contain the spread [3].
The vaccine, developed by the small American biotech company Dalan Animal Health, sidesteps a problem that had seemed intractable. There are no antibodies to prime. There are no memory lymphocytes. Instead, Dalan's approach delivers killed whole-cell P. larvae into the colony by mixing the inactivated bacteria into sugar syrup or a candy paste that worker bees consume and pass to the queen through her royal jelly [2][8]. Once inside the queen, fragments of the dead bacteria bind to a single carrier protein, and that protein does something remarkable.
A Yolk Protein That Carries a Warning
The carrier is vitellogenin, a large glycoprotein that, in most animals, is best known as a yolk precursor. In honeybees, vitellogenin does double duty. A 2014 study by Dalial Freitak and colleagues showed that when a queen is exposed to heat-killed P. larvae, vitellogenin binds to bacterial molecules such as lipopolysaccharides and fragments of peptidoglycan in the hemolymph (the insect circulatory fluid) and ferries them into her developing eggs [4]. A follow-up paper the next year identified the immune-priming function of vitellogenin directly, showing that this single yolk protein is the conduit by which a queen's experience becomes her daughters' protection.
The mechanism reframes what vaccination means in a non-vertebrate. There is no immune system to "train" in the textbook sense. There is, instead, a cargo system. Bacterial fingerprints travel into the egg, and when the larva hatches and consumes its own yolk, those fingerprints are waiting. Efficacy studies published in 2022 in Frontiers in Veterinary Science showed that larvae from vaccinated colonies die at rates 30 to 50 percent lower than controls when challenged with P. larvae, enough to keep the disease from manifesting in the hive at all [1][3]. The honeybee immune system is, in effect, borrowing a trick from vertebrate vaccination without needing any of the cellular infrastructure that trick usually requires.
From Beehives to Shrimp Ponds
If the bee vaccine proves the trick works in one insect, the natural next step is to test it in another. Dalan Animal Health is now developing a multivalent vaccine for Pacific white shrimp (Litopenaeus vannamei), the most heavily farmed shrimp on Earth, against Vibrio species, the bacterial genus responsible for most of aquaculture's worst disease outbreaks [5].
The economic stakes are different in scale but the same in shape. Aquaculture now produces roughly half of all shrimp consumed globally, and disease is the single largest cause of economic loss in the industry, costing an estimated $6 billion every year [9]. Independent researchers have already shown that the principle works in crustaceans: a 2018 study in Fish & Shellfish Immunology found that maternally primed shrimp larvae, those whose mothers were exposed to heat-killed Vibrio harveyi, survived subsequent bacterial challenge at significantly higher rates than unprimed larvae, and the protection extended through larval development into the post-larval stages [6]. Dalan's product is, in essence, a domesticated version of that natural priming, wrapped in a regulatory package and scaled for hatcheries.
What the Vaccine Reveals About Immunity Itself
The deeper implication of all this is not about bees or shrimp. It is about the neat textbook distinction between innate and adaptive immunity, a distinction built on the observation that vertebrates mount specific, long-lasting immune responses via B cells and T cells, while invertebrates mount only general, short-lived ones. That distinction is now visibly incomplete.
A 2024 review in Frontiers in Immunology catalogued a decade of evidence that invertebrates, from crustaceans to insects, exhibit a form of immune memory that is heritable across generations and is mediated not by antibodies but by epigenetic modifications, chemical marks on DNA and its associated histone proteins that change which genes are turned on without changing the genes themselves [7]. Honeybees and shrimp are not, in any literal sense, generating antibodies. They are doing something functionally analogous through a different molecular logic, and the protection passes from parent to offspring through maternal transfer and, in some cases, through changes to the inherited chromatin itself.
"Like other insects, honeybees don't generate antibodies, so until recently they have been overlooked in the quest for vaccines."
Anna M. Kriebs wrote that in Nature Biotechnology in early 2023, summarizing a consensus that the bee vaccine was about to overturn [1]. Overlooked, but not unprotected. The mechanism is different. The outcome is not.
There is genuine scientific debate about the precise molecular details. Some researchers emphasize vitellogenin's role as a physical carrier of bacterial fragments. Others point to differential methylation patterns in the hemocytes (the insect immune cells) of primed individuals. The two accounts are not mutually exclusive, and the field is still working out which dominates in which species, and under which conditions [7]. What is no longer in serious dispute is the result.
What Comes Next
Dalan's pipeline now includes vaccines for European Foulbrood, caused by Melissococcus plutonius, and for chalkbrood, a fungal disease, both still in development for honeybees [1]. The company also holds patents extending the same maternal-transfer platform to silkworms and other economically important insects [1]. As of late 2024, the shrimp vaccine is in active trials [5].
The practical consequences are immediate. Honeybees contribute an estimated $20 billion in pollination value to U.S. agriculture every year, and U.S. beekeepers have been losing 30 to 40 percent of their colonies annually, with disease as a leading cause [10]. A vaccine that works at the level of the egg, in an animal with no antibodies, is a small, strange, very specific tool, and it is arriving at the moment when beekeepers need new ones badly.
The larger consequence is a quiet rewriting of how biologists think about animal immunity. The line between creatures that "have" immune memory and creatures that "do not" has, for a century, been drawn along the spine, vertebrates on one side, invertebrates on the other. That line is now, in the light of vitellogenin and histone marks and $6 billion in shrimp losses, visibly more porous than it used to be. The vaccine did not break the binary. It just made the cracks too interesting to ignore.